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Advanced adenocarcinoma of the pancreas has a very poor prognosis. The aim of this study was to assess the efficacy and tolerability
of a combination of the chemotherapeutic agents gemcitabine and raltitrexed. Chemonaı ¨ve patients with advanced adenocarcinoma
of the pancreas were treated with a combination of raltitrexed (3.5mgm
 2 on day 1 of a 21-day treatment cycle) and gemcitabine
(800mgm
 2 intravenously (i.v.) on days 1 and 8 of a 21-day cycle). Between April 2000 and February 2003, 27 patients were
enrolled onto the study. The mean duration of treatment was 11 weeks. Four of 27 patients experienced at least one episode of
grade 3 or 4 neutropenia. One patient with grade 4 neutropenia died due to sepsis. Four of 27 patients experienced grade 4
diarrhoea. There was one partial remission (4%) and 12 patients experienced disease stabilisation (44%). The 6-month and 1-year
survival rates were 37 and 11%, respectively. Symptomatic benefit occurred in seven (26%) patients. We conclude that a combination
of raltitrexed and gemcitabine, using the schedule and doses in this study, cannot be recommended for patients with advanced
pancreatic cancer.
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Adenocarcinoma of the pancreas is a disease that rapidly leads to
fatality, which causes annually over 40000 deaths in Europe
(Pisani et al, 1999) and more than 210000 world wide (Parkin et al,
2001). The median survival of untreated patients is 3 months
(Palmer et al, 1994; Glimelius et al, 1996). A median survival of up
to 14.3 months can be achieved with radical surgery, but this is
possible in less than 20% of patients, as pancreatic carcinoma
tends to present late in its course (Conlon et al, 1996; Haycox et al,
1998).
All other patients, with unresectable disease, are potential
candidates for systemic treatment, although unfortunately, pan-
creatic carcinomas are rather chemoinsensitive (Kornmann et al,
1999). In a study of patients with advanced pancreatic cancer by
Burris et al, gemcitabine provided clinical benefit to 24% of
patients compared to 5% with 5-fluoruracil (5-FU), and the
survival rate at 12 months was 18% for gemcitibine patients
compared to 2% for 5-FU patients (Burris et al, 1997). No single
agent or combination of agents has been proven superior to
gemcitabine alone, and although the objective response is low
(below 10%), gemcitabine is the drug of choice for patients with
advanced pancreatic cancer (Burris et al, 1997; Shore et al, 2003).
Recent advances in cancer genetics have led to the development
of novel rationally designed chemotherapeutic agents. A promising
target for pancreatic cancer therapy is the K-Ras oncogene product
and its signalling pathway. K-Ras mutations that encode for
activated proteins are found in more than 90% of all pancreatic
cancers (Jaffee et al, 2002; Shore et al, 2003). In order to bind to the
cell membrane, Ras protein has an additional farnesyl group.
Raltitrexed (Tomudex
s; AstraZeneca Pharmaceuticals, Holland) is
a quinazoline folate analogue, which acts as a pure and specific
thymidylate synthetase (TS) inhibitor, designed to inhibit K-ras
protein farnesylation. In vitro single dosing has shown a similar
duration of inhibition of TS as bolus 5-FU (Ford et al, 2002). Large
randomised studies of raltitrexed have demonstrated equivalent
response rates and reduced toxicity compared to the combination
of 5-FU and leucovorin in colorectal cancer (Cunningham, 1998).
A phase II study with raltitrexed in patients with pretreated
pancreatic cancer showed a response rate of 5% (Pazdur et al,
1995).
Owing to some single agent efficacy, a nonoverlapping toxicity
profile and a difference in mechanism of action, raltitrexed is an
interesting agent to combine with gemcitabine. In order to assess
the efficacy and tolerability of the combination of raltitrexed and
gemcitabine in patients with nonresectable advanced pancreatic
cancer, a multicentre phase II trial was started in April 2000.
PATIENTS AND METHODS
Study design objectives
The primary objective of this phase II study was to determine the
efficacy of a combination of gemcitabine and raltitrexed in
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sadvanced or metastatic adenocarcinoma of the pancreas. Second-
ary objectives were to determine the duration of objective response
and to evaluate the toxicity profile of this treatment.
Patient eligibility
Patients with inoperable advanced or metastatic adenocarcinoma
of the pancreas had to be chemonaı ¨ve. Further inclusion criteria
consisted of histologically or cytologically proven pancreatic
adenocarcinoma, a World Health Organization (WHO) status of
two or less and the presence of a two-dimensional measurable
lesion of at least 1cm. Patients had to be older than 18 years with
an estimated life expectancy of at least 8 weeks. Adequate organ
function was defined as: a haemoglobin level X6.5mmoll
 1,a
white blood cell count X4000ml
 1, a platelet count X100000ml
 1,
a creatinine clearance of X65mlmin
 1 (calculated according to
the formula of Cockcroft and Gault, 1976), bilirubin levels p3
times the upper normal laboratory value, serum transaminase
levels o2.5 times the normal laboratory values without known
liver involvement or o5 times the normal laboratory values with
known liver involvement. Patients who had been treated with
radiotherapy for pancreatic cancer, and patients with symptomatic
cerebral or leptomeningeal metastases were excluded. The local
ethics committees approved this study and written informed
consent was obtained from all patients before entry to the study.
Treatment protocol
Raltitrexed (Tomudex
s) was administered intravenously (i.v.) at a
dose of 3.5mgm
 2 over 15min on day 1 of a 21-day treatment
cycle. Gemcitabine (Gemzar
s; Eli Lilly, Indianapolis, USA) was
administered at a dose of 800mgm
 2 i.v. over 30min on days 1
and 8 of a 21-day cycle. Courses were administered every 3 weeks,
as long as patients benefited, and there was no evidence of
progressive disease (PD).
Adverse reactions were evaluated according to Common
Toxicity Criteria of the National Cancer Institute of Canada (NCI
– CTC). In the event of clinically relevant toxicity during the first
cycle of treatment, dosing was delayed until all signs of toxicity
had resolved or at least improved. Any patient who required more
than 14 days for recovery was removed from the study. For all
further cycles, administered doses were based on toxic effects
observed during the previous cycle. In the case of grade 3 or 4
haematological toxicity requiring more than 1 week delay of the
next treatment cycle, or febrile neutropenia, both drug doses were
reduced by 25% for subsequent cycles. The raltitrexed dose was
reduced to 75 or 50%, respectively, if grade 3 or 4 nonhaemato-
logical toxicity occurred during the previous treatment cycle.
Doses of both chemotherapeutic agents were reduced in the case of
grade 2 or 3 diarrhoea and discontinued in the case of grade 4
diarrhoea. In the event of renal function impairment, raltitrexed
was reduced to 75 or 50%, if creatinine clearance was 55–65 or
25–54mlmin
 1, respectively. In both cases cycle duration was
extended to 28 days. When creatinine clearance was less than
25mlmin
 1, raltitrexed treatment was terminated. In the case of
grade 3 or 4 toxicity after a dose reduction, patients were removed
from the study.
Clinical evaluation
Toxicity analyses were applied to patients who received at least one
course of chemotherapy, while response evaluation was assessed
after every two cycles of chemotherapy, either using a CT scan or
clinically according to WHO standard criteria (Miller et al, 1981).
Subjective symptoms (pain score, analgesic use and performance
status), serious adverse reactions, physical examination, perfor-
mance status and other clinical benefit response parameters were
recorded before each treatment cycle.
Statistics
According to the optimal two-stage design, for a target activity
level of at least 20% response rate, two objective responses had to
be observed in the first 21 assessable patients (alpha and beta error
probabilities 0.005 and 0.01, respectively), otherwise this trial
would be terminated. Time-related parameters were analysed using
Kaplan–Meier on an intention-to-treat analysis.
RESULTS
Between April 2000 and February 2003, 27 patients from six
institutions were enrolled onto the study. All patients were eligible.
The main clinical characteristics at study entry are listed in Table 1.
The median age was 59 years (range 42–74 years) and the
performance status was 44, 44 and 11% for WHO 0, 1 and 2,
respectively. No patients had received radiotherapy or chemother-
apy prior to the study. In all, 16 (59%) patients had metastatic
disease at the time of registration. A total of 95 cycles were
administered (mean four cycles per patients, range 1–14). The
mean duration of treatment was 11 weeks.
Six patients (22%) did not start with the second course of
chemotherapy due to objective or subjective toxicity and were not
assessable for efficacy (Table 2). One (4%) patient showed a partial
response (95% CI-3–11%). A total of 12 (44%) patients showed
disease stabilisation or a minor response with a median duration
of 3 months (range 2–7 months). In eight patients (30%), the
tumour was progressive despite treatment. The overall median
survival was 5.5 months (range 1–16 months). The median time to
progression was 3.4 months (range 0–12 months). At the time of
study evaluation, two patients were still alive at 99 and 106 days of
follow-up. The 6-month and 1-year survival was 37 and 11%,
respectively.
The toxicity for up to six treatment cycles was evaluated for all
patients and results are summarised in Table 3. Four patients were
unwilling to undergo further treatment because of subjective
toxicity. Haematological toxicities were grades 3–4 in four patients
with leucopoenia and in three patients with thrombocytopenia.
One patient with grade 4 leucopoenia died due to septicaemia.
Elevated transaminases and alkaline phosphatase were frequently
observed in the patients. However, these abnormalities were
Table 1 Patient characteristics
Characteristic n
Number of patients 27
Age (years)
Median 59
Range 42–74
Female/male 13/14
Disease at presentation
Locally advanced 11
Metastatic 16
WHO performance status
01 2
11 2
23
WHO pain intensity
06
16
26
38
41
Weight loss 45% pretreatment 13
WHO¼World Health Organization.
Phase II study pancreatic carcinoma
JJ Arends et al
446
British Journal of Cancer (2005) 92(3), 445–448 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sself-limiting. In eight patients, transaminases were elevated before
entry to the study and were therefore most probably disease
related. Grade 1–2 nausea occurred in 41% of the treatment cycles.
Grade 1–3 diarrhoea occurred in 17% of cycles, leading to
hospitalisation in four (15%) patients. In two patients, with grade 2
and 3 diarrhoea, respectively, the doses of gemcitabine and
ralitrexed were not reduced according to the protocol. Both
patients experienced grade 4 diarrhoea in the following treatment
cycle. No dose modifications for renal impairment needed to be
performed over the first six treatment cycles.
Five of the 27 patients who reported pain at study entry reported
less pain after treatment and two patients experienced weight gain.
Therefore, seven patients (26%) were classified as clinical benefit
responders. Four patients (15%) were stable in both primary (ie
pain intensity and WHO performance status) and secondary
(weight) parameters.
DISCUSSION
The effects of 5-FU in pancreatic carcinoma have been extensively
studied and reported response rates for single agent 5-FU
treatment in patients with pancreatic cancer range from 0 to
19% (Warshaw and Fernandezdelcastillo, 1992; Haller, 2003).
Although gemcitabine is generally approved as a first-line
treatment for advanced pancreatic cancer, the objective responses
are low and the median survival benefit is modest in comparison
with 5-FU alone (Burris et al, 1997). Owing to disappointing results
from chemotherapy in pancreatic cancer, combination regimens
have now been developed. Combinations of 5-FU-like drugs and
gemcitabine show synergistic antitumour activity in vitro (Ren
et al, 1998; Peters et al, 2000). In patients with advanced cancer, it
has been shown that gemcitabine increases systemic 5-FU
exposure (Correale et al, 2003a), and several studies have tested
the combination of these two drugs in pancreatic cancer with
response rates of up to 31% and median survival rates of up to
more than 1 year (Correale et al, 2003b; Lee et al, 2004). One
randomised phase III study with gemcitabine in combination with
5-FU vs gemcitabine alone did not demonstrate any improvement
in median survival (Berlin et al, 2002). However, 5-FU was given as
a bolus infusion and there is evidence that continuous infusion
might be superior to bolus administrations (Hansen et al, 1988;
Aschele et al, 1992; Hidalgo et al, 1999). Thus, the method of
administration may have influenced the outcome of the study by
Berlin et al and so the combination of these two drugs remained
attractive.
A full paper was published on one study by Kralidis et al (2003)
involving the combination of raltitrexed and gemcitabine in
patients with locally advanced and metastatic pancreatic cancer.
In this study, the patients were treated with raltitrexed (3mgm
 2
in 15min infusion) on day 1 and gemcitabine (1000mgm
 2)o n
days 1 and 8. In comparison to our study, patients had worse
prognostic factors (Cubiella et al, 1999), that is, 20% of patients
had a WHO score of 0 compared to 44% in our study and 84% of
patients had metastatic disease compared to 59% in our study. The
reported 1-year survival (11%) and tumour growth stabilisation
rate (overall responseþstable disease) are more or less equal in
both studies, but the reported response rates differ (12% compared
to 4% in our study). We used a relatively high dose of bolus
raltitrexed in combination with a lower dose of gemcitabine.
Laboratory research on the effects of raltitrexed on elevation of
plasma 20 deoxyuridine as a marker for TS inhibition suggests that
there is a plasma drug level above which no further TS inhibition is
accomplished (Ford et al, 2002). Thus, high plasma concentrations
of raltitrexed after bolus infusion might be responsible for the
increased amount of gastrointestinal toxicity in our patients,
without an increase in therapeutic effect. In our study, seven
patients stopped further chemotherapy due to subjective or
objective toxicity. One of these patients had a potential partial
response, but this could not be confirmed objectively. The
difference observed between these studies may also be caused by
the relatively low dose of gemcitabine administered to our patients.
Preclinical data using human tumour cell lines indicated a possible
dose–response relationship, suggesting that exposure to a higher
concentration of gemcitabine might correlate with improved
clinical effectiveness (Von Hoff, 1996).
The reported 1-year survival and clinical benefit ratios in our
study and the study of Kradalis et al are not better than the results
reported with gemcitabine as a single agent (Burris et al, 1997).
One reason for this could be related to the design of both studies.
Preclinical data suggest that gemcitabine given before 5-FU
produces more synergistic antitumour activity in pancreas
carcinoma cell lines (Correale et al, 2000). In our study and the
study of Kradalis et al, gemcitabine was administered after the
raltitrexed. In our study, gemcitabine was administered as a 30min
infusion and not as a fixed dose rate (FDR). In a randomised phase
II study by Tempero et al (2003) comparing gemcitabine treatment
as a standard 30min infusion to administration at an FDR of
10mgm
 2min
 1 over 150min, the 1- to 2- and even 3-year
survival rates were in favour of the FDR. This was also seen in a
phase II study in which patients with advanced pancreatic cancer
given FDR gemcitabine in combination with an oral fluoropyr-
imidine had a median survival of almost 1 year (Feliu et al, 2002).
We conclude that this combination of raltitrexed and gemcita-
bine given in a sequential schedule has a moderate activity. There
is no evidence suggesting that this combination is advantageous
over gemcitabine or 5-FU alone in the treatment of advanced
pancreatic cancer.
ACKNOWLEDGEMENTS
We thank Astra Zeneca Pharmaceuticals, The Netherlands for the
drug supply for this study.
Table 2 Overall objective response
No. of patients (n¼27) %
PR 1 4
SD 12 44
PD 8 30
Not assessable 6 22
PR¼partial response; SD¼stable disease; PD¼progressive disease.
Table 3 Toxicity
WHO grade
Toxicity 1 2 3 4
Anaemia 9 (19) 4 (5) — 1 (1)
Leucopoenia 3 (9) 4 (6) 0 (1) 4 (4)
Thrombocytopenia 0 (2) — 3 (3) —
Elevated ASAT 10 (30) 5 (7) 4 (5) 1 (1)
Elevated ALAT 9 (23) 6 (12) 8 (10) —
Elevated alkaline phosphatase 7 (23) 9 (12) 2 (2) —
Elevated bilirubin 2 (2) 1 (1) 2 (2) 4 (4)
Nausea 8 (29) 7 (12) 7 (7) —
Vomiting 9 (16) 8 (10) 2 (2) —
Diarrhoea 6 (8) 0 (2) 2 (3) 4 (4)
Mucositis 4 (5) — 2 (2) —
Cutaneous 2 (6) 2 (3) — —
Flu-like symptoms 4 (9) 5 (7) — —
ASAT¼serum glutamic oxaloacetic transaminase; ALAT¼serum glutamic pyruvic
transaminase; WHO¼World Health Organization.
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